Company:  INCYTE CORP (INCY)
Form Type:  10-K
Filing Date:  2/22/2012 
CIK:  0000879169 
Address:  ROUTE 141 & HENRY CLAY ROAD
BUILDING E336
 
City, State, Zip:  WILMINGTON, Delaware 19880 
Telephone:  (302) 498-6700 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$47.30  
Change: 
0.34 (0.72%)  
Trade Time: 
Apr 24  
Market Cap: 
$7.83B
Description of Business
Incyte is a drug discovery and development company focused on developing proprietary small molecule drugs to treat serious unmet medical needs. We have a broad pipeline with programs focused primarily in the areas of oncology and inflammation. We focus our efforts on clinical programs that we believe have the greatest likelihood of creating near-and long-term value and on compounds that we believe a company of our size can effectively develop and commercialize on its own, or that we can further develop and commercialize through strategic relationships. Our highest priority programs involve our janus kinase (JAK) inhibitors, which include oral INCB18424 for hematologic and oncology indications and oral INCB28050 for chronic inflammatory and autoimmune diseases.
Register for EDGAR Pro and access this filing in:     
  FORM 10-K
    Item 1A. Risk Factors
    Item 1B. Unresolved Staff Comments.
    PART I
      Item 2. Properties
      Item 3. Legal Proceedings
      Item 4. Mine Safety Disclosures
    PART II
      Item 5. Market for Registrant's Common Equity, Related ...
      Item 6. Selected Financial Data
      Item 7. Management's Discussion and Analysis of Financial ...
        Results of Operations
      Item 7A. Quantitative and Qualitative Disclosures About ...
      Item 8. Financial Statements and Supplementary Data
        REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
        BALANCE SHEET
        INCOME STATEMENT
        STOCKHOLDERS EQUITY
        CASH FLOW
        NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
      Item 9. Changes in and Disagreements with Accountants on ...
      Item 9A. Controls and Procedures
      Report of Independent Registered Public Accounting Firm
      Item 9B. Other Information
    PART III
      Item 10. Directors, Executive Officers and Corporate Governance
      Item 11. Executive Compensation
      Item 12. Security Ownership of Certain Beneficial Owners ...
      Item 13. Certain Relationships and Related Transactions, ...
      Item 14. Principal Accountant Fees and Services
    PART IV
      Item 15. Exhibits, Financial Statement Schedules
    SIGNATURES
    EXHIBIT INDEX
  EXHIBIT 10.28
  EXHIBIT 10.29
  EXHIBIT 12.1
    RATIO COMPUTATION
  EXHIBIT 21.1
  EXHIBIT 23.1
    Consent of Independent Registered Public Accounting Firm
  EXHIBIT 31.1
    CERTIFICATION
  EXHIBIT 31.2
    CERTIFICATION
  EXHIBIT 32.1
  EXHIBIT 32.2
BROKERAGE PARTNERS